Combination of 6-Thioguanine, Procarbazine, Lomustine, and Hydroxyurea for Patients with Recurrent Malignant Gliomas
- 1 November 1996
- journal article
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 39 (5) , 921-926
- https://doi.org/10.1097/00006123-199611000-00006
Abstract
To determine the efficacy of the combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas after failure of either previous radiotherapy alone or previous radiotherapy plus nitrosourea-based chemotherapy. Seventy-seven patients with recurrent malignant gliomas were studied. 6-Thioguanine was administered for 4 days before lomustine, and procarbazine was administered for 1 day before and 2 days after lomustine to potentiate lomustine's antitumor effect. Hydroxyurea was initiated 1 day before lomustine and continued for a total of 3 days. Thirty patients with glioblastomas and 47 patients with anaplastic gliomas were eligible for evaluation. In the glioblastoma group, 2 of 30 patients had a partial response and 8 of 30 patients had stable disease. This group of patients who responded and had stable disease included 6 of 10 patients who had not undergone previous chemotherapy but only 4 of 20 who had undergone previous chemotherapy. The overall median time to disease progression for the glioblastoma group was 9 weeks. In the anaplastic glioma group, 11 of 47 patients had a partial response and 25 of 47 had stable disease, including 23 of 30 without previous chemotherapy and 13 of 17 who had undergone previous chemotherapy. The median time to disease progression for the whole anaplastic glioma group was 24 weeks; however, the time to disease progression was 50 weeks for responding patients who had not undergone previous chemotherapy and 25 weeks for those who had undergone previous chemotherapy. Our results indicate that chemotherapy with a combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea is active for patients with recurrent anaplastic gliomas and glioblastomas not previously treated with nitrosourea-based chemotherapy but is inactive for patients with glioblastomas previously treated with chemotherapy.Keywords
This publication has 12 references indexed in Scilit:
- Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiformeInternational Journal of Radiation Oncology*Biology*Physics, 1995
- Influence of O6‐methylguanine‐DNA methyltransferase activity on chloroethylnitrosourea chemotherapy in brain tumorsInternational Journal of Cancer, 1993
- Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study.Journal of Clinical Oncology, 1992
- Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance.Journal of Clinical Oncology, 1992
- Mechlorethamine, vincristine, and procarbazine chemotherapy for recurrent high-grade glioma in adults: a phase II study.Journal of Clinical Oncology, 1990
- Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failureNeurology, 1990
- Differential response to 1,3‐bis (2‐chloroethyl)‐1‐nitrosourea in drug‐resistant and ‐sensitive 9L rat brain tumor cells pretreated with α‐difluoromethylornithine and 6‐thioguanineInternational Journal of Cancer, 1989
- Inhibition of the hepatic o6-alkylguanine-DNA alkyltransferase in vivo by pretreatment with antineoplastic agentsBiochemical Pharmacology, 1989
- Potentiation of 1,3-BIS(2-chloroethyl)-1-nitrosourea (BCNU)-induced cytotoxicity in 9L cells by pretreatment with 6-thioguanineBiochemical Pharmacology, 1985
- CLINICAL PHARMACOLOGY OF THE NITROSOUREASPublished by Elsevier ,1981